Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(33%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_3
3
50%
Ph phase_4
1
17%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Other(2)

Detailed Status

Completed2
unknown1
Recruiting1
Suspended1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 33 (60.0%)
Phase 41 (20.0%)

Trials by Status

unknown117%
completed233%
recruiting117%
suspended117%
active_not_recruiting117%

Recent Activity

2 active trials
Showing 5 of 6
active_not_recruitingphase_2

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

NCT04957485
suspendedphase_3

Tecovirimat in Non-hospitalized Patients With Monkeypox

NCT05534165
recruitingphase_3

Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease

NCT05597735
unknown

Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure

NCT02080767
completedphase_4

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

NCT04485039
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04957485Phase 2

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

Active Not Recruiting
NCT05534165Phase 3

Tecovirimat in Non-hospitalized Patients With Monkeypox

Suspended
NCT05597735Phase 3

Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease

Recruiting
NCT02080767

Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure

Unknown
NCT04485039Phase 4

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

Completed
NCT02474589Phase 3

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6